Corrective Phases R...
Health Care: Drugs
Delcath Systems Inc. (DCTH: NASDAQ)
$1.46 0.02 | 1.39%
06/04/12 - 11:55 AM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | n.a. | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.73 | 0.94 | 0.98 |
| Price to Sales (TTM) | 0.00 | 4.21 | 1.42 |
| Price to Book (MRQ) | 4.31 | 3.38 | 2.41 |
| Price to Tangible Book (MRQ) | 4.31 | -8.72 | 5.08 |
| Price to Cash Flow (TTM) | -1.70 | 274.70 | 9.80 |
| Price to Free Cash Flow (TTM) | -1.50 | -63.90 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.00 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 1.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 23.61 | -0.76 |
| Payout Ratio (TTM) | 0.00 | n.a. | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 37.70 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | n.a. | 1.60 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 7.01 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 225.80 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 225.80 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 51.14 | 4.51 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 2.40 | 1.40 | 1.10 |
| Current Ratio (MRQ) | 2.60 | 2.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.90 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.91 | 0.96 |
| Interest Coverage (TTM) | n.a. | 0.70 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 54.60 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 54.70 | 47.70 |
| EBITD Margin (TTM) | n.a. | 17.90 | 18.90 |
| EBITD - 5 Yr Avg | n.a. | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | -1.60 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | -1.20 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | n.a. | -0.01 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | -1.20 | 7.00 |
| Return on Assets (TTM) | -171.40 | -0.40 | 3.10 |
| Return on Assets - 5 Yr Avg | -72.40 | -0.60 | 2.50 |
| Return on Investment (TTM) | -261.00 | -0.60 | 7.90 |
| Return on Investment - 5 Yr Avg | -104.00 | -0.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 0.00 | 379,608.00 | 449,376.00 |
| Net Income/Employee (TTM) | -549,075.00 | -4,557.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 6.60 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 2.90 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.50 | 0.40 |
Portfolios with DCTH
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserROSIE
- UserTA stocks
- ContributorBarron's Activist Stocks 8-...
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- Contributor10 Biotech Stocks on Clinic...
- ContributorBarron's Insider Purchases ...
- User52 Week High Strategy
Latest DCTH Headlines from TheStreet
- BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- Biotech Stock Mailbag: Mela Sciences 09.09.11 | 06:09 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- Biotech Stock Mailbag: Celsion 05.13.11 | 08:05 am
- 'Mad Money Lightning Round': Go for Exelixis 04.26.11 | 07:04 pm
- Biotech Stock Mailbag: Amarin 04.22.11 | 07:04 am
- Sweet Spot in Biotech Investing 04.13.11 | 12:04 pm
- Delcath: Safety Questions Behind FDA Delay 02.23.11 | 07:02 am
- Delcath Hit With FDA Approval Delay 02.22.11 | 10:02 am
- 10 Health Care Stocks With 100% Buy Ratings 01.28.11 | 07:01 am
Press Releases for DCTH
- Delcath Announces First CHEMOSAT Procedures In Germany - PR Newswire 02.27.12 | 06:02 am
- Delcath Announces Updated Efficacy Results From Phase 3 Trial Of Chemosaturation For Melanoma Metastases In The Liver Presented At European Multidisciplinary Cancer Congress - PR Newswire 09.23.11 | 06:09 pm
- Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE - PR Newswire 09.13.11 | 02:09 am
- Delcath Systems Receives Refusal To File Letter From FDA - PR Newswire 02.22.11 | 05:02 am
- Delcath Achieves ISO 13485 Certification - PR Newswire 02.17.11 | 09:02 am
- Delcath Completes New Drug Application Submission To The FDA For The Chemosaturation Delivery System - PR Newswire 12.22.10 | 07:12 am
- Delcath Submits CE Mark Technical File For Hepatic ChemoSAT⢠Delivery System - PR Newswire 12.06.10 | 06:12 am
- Delcath Names Bernard R. Tyrrell As Senior Vice President For North American Sales And Marketing - PR Newswire 12.01.10 | 06:12 am
- Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010 - Business Wire 11.10.10 | 05:11 pm
- Delcath Systems Announces Third Quarter Progress Report Conference Call - PR Newswire 10.27.10 | 06:10 am
Partner Headlines for DCTH
- Active Stock Alerts: Dendreon, Delcath Systems, Johnson & Johnson, Boeing, Onyx June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Hyper-Novel Investments For Targeting Cancer - Seeking Alpha 05.30.12 | 09:05 am
- Mid-Day Update: Stocks Trending Water Ahead of First Holiday Weekend of Summer - NASDAQ 05.25.12 | 04:05 pm
- Mid-Day Market Losers - Benzinga 05.25.12 | 01:05 pm
- 4 Stocks Attracting Heavy Trading Interest - Wall St. Cheat Sheet 05.25.12 | 12:05 pm
- Ultimate Market Recap: Talbots Tanks, Facebook Fiasco Continues - Wall St. Cheat Sheet 05.25.12 | 06:05 am
- Company News for January 03, 2012 - Corporate Summary - Zacks 01.03.12 | 10:01 am
- Emisphere: Crown Jewel In Oral B12 - Seeking Alpha 10.07.11 | 09:10 am
- Delcath Announces Updated Efficacy Results from Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver - Benzinga 09.23.11 | 06:09 pm
- Friday's Top Performing Small Cap Stocks (MDS, MNKD, FXCM, FOE, DCTH) - NASDAQ 08.15.11 | 01:08 pm
